Bayer Secures Multiple Procurement Deals at the 6th CIIE
At the 6th China International Import Expo (CIIE) in Shanghai, Germany-headquartered Bayer (ETR: BAYN) announced...
ETR: BAYN
ayer Partners with Changzhou Qianhong Bio-pharma to Advance Digestive Health Solutions
Germany-headquartered Bayer (ETR: BAYN) has entered into a partnership with China-based Changzhou Qianhong Bio-pharma Co.,...
Bayer’s Q3 2023 Financial Report: A Mixed Bag with Consumer Health Driving Growth
Germany-based major Bayer (ETR: BAYN) published its financial report for the third quarter of 2023,...
Bayer and Shanghai Pharmaceuticals Launch Co.Lab to Incubate Life Sciences Innovation in China
Bayer, the Germany-headquartered multinational pharmaceutical and life sciences company (ETR: BAYN), has entered into a...
Bayer Unveils Real-World Insights on Kerendia for CKD and T2D Management
Germany-headquartered Bayer (ETR: BAYN) recently published interim insights from a significant real-world observational study focusing...
Bayer HealthCare Launches First Innovation Center in Beijing’s ETown
Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated...
Bayer Partners with HALO Precision Diagnostics to Develop Gadoquatrane for MRI Applications
Germany-based Bayer (ETR: BAYN) has announced a strategic partnership with US radiology expert HALO Precision...
Bayer AG Plans Continued Investment in China Amidst Global Challenges
Germany-based multinational corporation Bayer AG (ETR: BAYN) is determined to continue investing in China, as...
Bayer Opens First Cell Therapy Production Facility in the U.S. to Advance Research
Bayer AG (ETR: BAYN) has inaugurated its first production site dedicated to cell therapies, marking...
Bayer Partners with Twist Bioscience for Antibody Discovery in Multiple Disease Areas
German pharmaceutical giant Bayer (ETR: BAYN) has entered into a strategic partnership with drug discovery...
China’s NHC Expands Rare Disease List, Includes 21 Cancer Types
The National Health Commission (NHC) of China has released an updated national list of rare...
Bayer Subsidiary’s Parkinson’s Treatment Bemdaneprocel Shows Promise in Phase I
Germany-based Bayer (ETR: BAYN) has announced that its subsidiary BlueRock Therapeutics’ open-label Phase I study...
Bayer Funds Landmark Trials for Kerendia in Heart Failure Treatment Expansion
Germany-based pharmaceutical company Bayer (ETR: BAYN) has announced funding for three investigator-sponsored collaborative studies aimed...
Bayer Partners with Mahana Therapeutics to Market Digital Health Technologies
Germany-headquartered Bayer (ETR: BAYN) has announced a strategic partnership with US digital developer Mahana Therapeutics....
Hua Medicine Achieves Development Milestone for HuaTangNing with Bayer Agreement
China-based Hua Medicine (HKG: 2552) has announced the achievement of a significant development milestone for...
Sandoz Achieves Primary Endpoint in Phase III Trial for Biosimilar Aflibercept
Switzerland-based Novartis (NYSE: NVS) subsidiary Sandoz (SWX: SDZ) has announced that a Phase III confirmatory...
Bayer AG Reports Q2/H1 2023 Financials with Challenges in Crop Science and Pharmaceuticals
Germany-based multinational Bayer AG (ETR: BAYN) has released its financial report for the second quarter...
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...
Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD
German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...
Bayer and Peking University Enter Fourth Phase of Partnership to Advance Drug Discovery
Germany-based pharmaceutical giant Bayer (ETR: BAYN) has entered its fourth phase of partnership with the...